Skip to main content
logo
Kezar Life Sciences, Inc. (KZR)
May 11, 2026 - KZR was delisted (reason: acquired by AUPH)
7.29
0.00 (0.00%)
Inactive · Last trade price on May 8, 2026

Kezar Life Sciences Income Statement

Millions USD. Fiscal year is Jan - Dec.
Fiscal Year
TTMFY 2025FY 2024FY 2023FY 2022FY 2021
Period Ending
Mar '26 Dec '25 Dec '24 Dec '23 Dec '22 Dec '21
Revenue
---7--
Revenue Growth
------
Cost of Revenue
33.7633.7665.7485.751.0138.94
Gross Profit
-33.76-33.76-65.74-78.7-51.01-38.94
Selling, General & Admin
18.2718.5123.3926.5420.1515.72
Research & Development
-10.64-----
Operating Expenses
7.6418.5123.3926.5420.1515.72
Operating Income
-41.39-52.27-89.14-105.24-71.16-54.66
Interest Expense
-0.55-0.9-1.6-1.6-1.19-0.16
Interest & Investment Income
3.634.448.4611.14.110.19
Other Non Operating Income (Expenses)
-0.47-0.470.010.05--
EBT Excluding Unusual Items
-38.78-49.2-82.27-95.68-68.24-54.63
Merger & Restructuring Charges
-7.45-6.84-1.47-6.19--
Pretax Income
-45.23-56.03-83.74-101.87-68.24-54.63
Net Income
-45.23-56.03-83.74-101.87-68.24-54.63
Net Income to Common
-45.23-56.03-83.74-101.87-68.24-54.63
Net Income Growth
------
Shares Outstanding (Basic)
777775
Shares Outstanding (Diluted)
777775
Shares Change
0.41%0.36%0.48%7.70%27.69%19.90%
EPS (Basic)
-6.17-7.66-11.49-14.04-10.13-10.35
EPS (Diluted)
-6.17-7.66-11.49-14.04-10.13-10.35
EPS Growth
------

Additional Metrics

Fiscal Year
TTMFY 2025FY 2024FY 2023FY 2022FY 2021
Period Ending
Mar '26 Dec '25 Dec '24 Dec '23 Dec '22 Dec '21
Free Cash Flow
-42.03-51.79-74.24-83.46-60.42-42.75
Free Cash Flow Per Share
-5.74-7.08-10.18-11.50-8.97-8.10
Operating Margin
----1503.39%--
Profit Margin
----1455.29%--
Free Cash Flow Margin
----1192.21%--
EBITDA
-40.7-51.37-88.1-104.17-70.14-53.15
D&A For EBITDA
0.690.91.041.071.021.51
EBIT
-41.39-52.27-89.14-105.24-71.16-54.66
SEC Filings: 10-K · 10-Q